Janssen Pharmaceuticals, Inc.

Glaxosmithkline Biologicals Sa

Janssen Vaccines & Prevention B.v.

Jan Theunis Poolman

Darren Robert Abbanat

Michael T Kowarik

Stefan Jochen Kemmler

Manuela Mally

Patricia Ibarra Yon

Veronica Gambillara Fonck

Jeroen Geurtsen

Michael L Wetter

Micha Andres Häuptle

Eveline Marleen Weerdenburg

Peter Wilhelmus Maria Hermans

Pieter Jan Burghout

Martin Edward Braun

Maria Paula Carranza Sandmeier

Bert Jacquemyn

Kellen Cristhina Fae

Michal Sarnecki

Bart Gustaaf M Spiessens

Frank Germaine F Struyf

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic. (ExPEC).

Methods of producing bioconjugates ofO-antigen polysaccharides, compositions thereof, and methods of use thereof

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic(ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates ofpolysaccharide antigen O75 covalently bound to a carrier protein for the prevention of invasive ExPEC disease.

Multivalent vaccine compositions and uses thereof

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic(ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates ofpolysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of(EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Methods and compositions for immune protection against extra-intestinal pathogenic

A bioconjugate of anglucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying theO4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of anglucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additionalO-antigen polysaccharides to induce antibodies against anglucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic(ExPEC).

Bioconjugates ofO-antigen polysaccharides, methods of production thereof, and methods of use thereof

Growing community of inventors

Haarlem, Netherlands

Jan Theunis Poolman